Gracell Biotechnologies

A Member of the AstraZeneca Group

Add To Watchlist
General Information
Company Name
Gracell Biotechnologies
Founded Year
2017
Location (Offices)
Shanghai, China +5
Founders / Decision Makers
Wei William Cao - Founder, Chairman and CEO
Number of Employees
41
Industries
Biotechnology, Health Care
Funding Stage
Post Ipo Equity
Social Media

Gracell Biotechnologies - Company Profile

Gracell Biotechnologies is a global clinical-stage biopharmaceutical company focused on developing autologous and allogeneic cell therapies for cancer and autoimmune diseases. As a member of the AstraZeneca Group, it benefits from a strong inhouse R&D system. The company's innovative FasTCAR and TruUCAR technology platforms, alongside the SMART CART™ technology modules, aim to overcome current challenges in CAR-T therapies. These challenges include extended manufacturing time, suboptimal T cell quality, and limitations in solid tumor and autoimmune disease treatment. Founded in 2017 and based in China, Gracell's recent $100.00MPost-IPO Equity investment on 07 August 2023 attracted investors such as RA Capital Management, OrbiMed, Vivo Capital, Adage Capital Management, Janus Handerson, Logos Capital, TCG Crossover, Exome Asset Management, and Pivotal Life Sciences.

Taxonomy: biopharmaceutical company, cell therapies, cancer treatment, autoimmune diseases, R&D system, FasTCAR technology, TruUCAR technology, SMART CART, clinical-stage pipeline, autologous therapies, allogeneic therapies, CAR-T therapies, solid tumors, immunotherapy

Funding Rounds & Investors of Gracell Biotechnologies (4)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $100.00M 9
RA Capital Management, investor in Gracell Biotechnologies's Post-IPO Equity round OrbiMed, investor in Gracell Biotechnologies's Post-IPO Equity round Vivo Capital, investor in Gracell Biotechnologies's Post-IPO Equity round Adage Capital Management, investor in Gracell Biotechnologies's Post-IPO Equity round Janus Handerson, investor in Gracell Biotechnologies's Post-IPO Equity round Logos Capital, investor in Gracell Biotechnologies's Post-IPO Equity round TCG Crossover, investor in Gracell Biotechnologies's Post-IPO Equity round Exome Asset Management, investor in Gracell Biotechnologies's Post-IPO Equity round
Pivotal Life Sciences 		07 Aug 2023
Series C $100.00M 1
Temasek Holdings, investor in Gracell Biotechnologies's Series C round
28 Oct 2020
Series B $85.00M - 25 Feb 2019
Series A Unknown - 01 Jan 2018

Latest News of Gracell Biotechnologies

View All

No recent news or press coverage available for Gracell Biotechnologies.

Similar Companies to Gracell Biotechnologies

View All
Caribou Biosciences - Similar company to Gracell Biotechnologies
Caribou Biosciences Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases
SQZ Biotechnologies - Similar company to Gracell Biotechnologies
SQZ Biotechnologies Unlocking the full potential of cell therapies for patients around the world
Cellenkos, Inc. - Similar company to Gracell Biotechnologies
Cellenkos, Inc.
Sonoma Biotherapeutics - Similar company to Gracell Biotechnologies
Sonoma Biotherapeutics Leading the Next Frontier of Cell Therapy
Kyverna Therapeutics - Similar company to Gracell Biotechnologies
Kyverna Therapeutics Harnessing the power of cell therapy in autoimmune disease.
Circle Decoration Circle Decoration

Want to dive deeper into Gracell Biotechnologies? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now